Treatment of Actinic Keratosis — NCD 129 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 129 governing actinic keratosis treatment coverage, with an effective date of March 7, 2026. This policy does not restrict coverage based on lesion or patient characteristics — and that's the part your billing team needs to understand cold.

CMS actinic keratosis coverage policy under NCD 129 in the CMS Medicare system is one of the cleaner coverage determinations you'll encounter. No prior authorization. No lesion-count thresholds. No patient eligibility criteria tied to age, skin type, or lesion location. Medicare covers destruction of actinic keratoses — full stop. The 2026 modification to this policy keeps that broad coverage intact, but the update is a reminder to audit your current billing against what the policy actually says, not what your team assumes it says.

The policy does not list specific CPT or HCPCS codes. That means your code selection for actinic keratosis billing depends on the destruction method your clinician uses, not on a payer-approved code list. That distinction matters — and we'll cover it in detail below.

Quick-Reference Table

CMS Actinic Keratosis Coverage Criteria and Medical Necessity Requirements 2026

The CMS coverage policy under NCD 129 is unusually permissive. Effective for services performed on and after November 26, 2001 — and reaffirmed by this 2026 modification — Medicare covers the destruction of actinic keratoses without restrictions based on lesion or patient characteristics.

Read that again. No restrictions based on lesion characteristics. No restrictions based on patient characteristics. That's a broader medical necessity standard than most dermatology teams realize.

This matters because many billing teams self-impose restrictions that don't exist in the policy. They hold claims for actinic keratosis cases where the lesion count is low, or where the patient is younger, or where the clinician chose observation over destruction. None of those factors are coverage limiters under NCD 129.

What Counts as "Destruction" Under This Policy

The policy recognizes a range of treatment approaches. Commonly performed treatments include cryosurgery with liquid nitrogen, topical drug therapy, and curettage. Less commonly performed treatments include dermabrasion, excision, chemical peels, laser therapy, and photodynamic therapy.

The coverage policy covers destruction across all of these methods. Your code selection changes based on which method your clinician uses — but the coverage determination does not change. Whether your provider reaches for liquid nitrogen or a laser, Medicare's position under NCD 129 is the same: the service is covered.

There is one approach that falls outside the destruction framework: observation. The policy notes that clinicians may choose to observe lesions over time, removing them only if specific clinical features suggest possible transformation to invasive squamous cell carcinoma. Observation is a legitimate clinical choice — but it is not a billable destruction service. If your clinician documents an observation visit without a destruction procedure, bill accordingly. Don't shoehorn an observation encounter into a destruction code.

Prior Authorization Under NCD 129

NCD 129 does not require prior authorization for actinic keratosis destruction. This is a national coverage determination, not a local coverage determination, so it applies across all Medicare Administrative Contractor jurisdictions without additional prior auth layers from CMS.

That said, your Medicare Advantage contracts are a different matter. If you bill Medicare Advantage plans, check each plan's policy individually. Medicare Advantage plans can impose prior authorization requirements that traditional Medicare does not. Don't assume NCD 129's lack of prior auth extends to your MA population.

Medical Necessity Documentation

No restrictions doesn't mean no documentation. Your medical record still needs to support the procedure performed. Document the lesion's location, clinical appearance, and the destruction method used. If your clinician uses a less common method — laser therapy, photodynamic therapy, chemical peel — the documentation should reflect the clinical rationale. That's not a coverage requirement under NCD 129, but it protects you in an audit.

The medical necessity bar here is low by design. Actinic keratoses carry malignant potential. CMS made a policy decision in 2001 to cover their destruction broadly, and the 2026 modification does not walk that back. Use that permissive coverage to your advantage — but document cleanly.

Coverage Indications at a Glance

CMS Actinic Keratosis Billing Guidelines and Action Items 2026

The modification effective March 7, 2026 doesn't flip any coverage criteria — but it does give your billing team a clear reason to audit your current processes against what NCD 129 actually says. Here's what to do.

CPT, HCPCS, and ICD-10 Codes for Actinic Keratosis Treatment Under NCD 129

NCD 129 does not list specific CPT, HCPCS, or ICD-10 codes. This is deliberate — the policy covers destruction of actinic keratoses without restricting by method, so CMS did not build a closed code list into the determination.

Your coding team should select codes based on the specific destruction method documented in the clinical record. Common code categories used in actinic keratosis billing include destruction of benign or premalignant lesions, photodynamic therapy administration, and curettage — but the correct code depends entirely on what your clinician did and documented.

A Note on Topical Drug Therapy Coding

Topical drug therapy for actinic keratoses sits at a coverage crossroads. The therapy itself is covered under NCD 129. But depending on the drug — fluorouracil, imiquimod, diclofenac, ingenol mebutate — and whether it's administered in-office or prescribed for home use, the billing pathway differs. In-office administration may bill under Part B. A written prescription filled at a pharmacy goes through Part D. Get this wrong and you get a claim denial or a coordination-of-benefits problem. If you're not certain how your specific drug and administration model maps to Part B vs. Part D, loop in your compliance officer before billing.

What This Means for Code Selection Audits

Because NCD 129 leaves code selection to the provider, your internal coding guidelines carry more weight than usual. Your chargemaster and charge capture tools should map each documented destruction method to the correct CPT code range. If your charge capture uses a single generic "AK destruction" charge code regardless of method, that's a problem — and it's one the 2026 policy modification should prompt you to fix now.